Upstream Bio (NASDAQ:UPB) Shares Gap Down – Here’s Why

Upstream Bio, Inc. (NASDAQ:UPB) gapped down prior to trading on Wednesday . The stock had previously closed at $27.81, but opened at $19.00. Upstream Bio shares last traded at $14.77, with a volume of 2,857,447 shares.

Analysts Set New Price Targets

UPB has been the subject of a number of recent research reports. Lifesci Capital started coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Evercore began coverage on Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Upstream Bio presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Upstream Bio Stock Down 31.6%

The company has a market cap of $472.84 million, a P/E ratio of -4.65 and a beta of 1.90. The stock has a 50 day moving average price of $28.25 and a two-hundred day moving average price of $23.18.

Hedge Funds Weigh In On Upstream Bio

A number of hedge funds have recently bought and sold shares of UPB. Norges Bank bought a new stake in Upstream Bio in the 4th quarter valued at about $78,264,000. UBS Group AG raised its position in shares of Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after buying an additional 1,533,972 shares in the last quarter. Pictet Asset Management Holding SA bought a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $20,991,000. Marshall Wace LLP boosted its stake in shares of Upstream Bio by 198.8% in the third quarter. Marshall Wace LLP now owns 867,999 shares of the company’s stock valued at $16,327,000 after buying an additional 577,473 shares during the period. Finally, Integral Health Asset Management LLC acquired a new stake in Upstream Bio during the third quarter worth approximately $10,816,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.